A Thymic Rejuvenation Protocol - Tesamorelin · Thymosin a1 · Rapamycin · Imeglimin · DHEA

#1

I used SuperBio (a no-code AI platform designed to accelerate biomedical discovery, drug development, and biological research) to design an evidence based Thymic Rejuvenation Protocol.

I asked it to review the literature, including Dr Fahy’s TRIIM protocol, etc. and design a better protocol using FDA (or similar regulators) approved medications.

Note that it immediately suggested pulsed rapamycin, which surprised me as we (and the AI) know that chronic rapamycin is detrimental to the thymus.

BTW also note that since that protocol looked very good for effectively integrating strength training with pulsed rapamycin, I asked it for a separate addendum protocol specifically on strength training which I will post too.

report_thymic_rejuvenation_protocol_for_patients.pdf (26.5 KB)

1 Like
#2

For the fellow enthusiasts in that forum, here is the scientific & clinical reference about that thymic rejuvenation protocol.

report_thymic_rejuvenation_protocol_scientific _reference.pdf (44.4 KB)

#3

And here is the strength training addendum for that protocol.

Purpose of this addendum. The 4-week thymopoiesis/clearance cycle described in the
parent protocol is structurally identical to a classical undulating periodization model (3:1
loading-to-deload). This document provides the mechanistic rationale for synchronizing
progressive resistance training with the protocol phases.

report_thymic_rejuvenation_strength_addendum.pdf (30.7 KB)

1 Like
#4

No HGH used?

#5

Tesamorelin does pretty much the same thing: it uses your pituitary to release growth hormone.

#6

I had a (very) long discussion with the AI for that protocol. Here is the part about Tesamorelin vs rhGH:

Tesamorelin vs. Recombinant Human Growth Hormone (rhGH)

:white_check_mark: Pros of Tesamorelin (vs. rhGH)

1. Preserves physiological pulsatility — the most important advantage

GH is secreted in 6–8 discrete pulses per 24h(primarily nocturnal); GH receptors downregulate under sustained GH elevation. Tesamorelin triggers a natural GH pulse from your own somatotrophs. rhGH — which the TRIIM trial used as a daily subcutaneous injection — creates sustained, non-physiological GH exposure that drives receptor desensitisation over time.

2. Intact feedback control — self-regulating safety net

Tesamorelin leaves the somatostatin brakefully operational:

Tesamorelin → Pituitary GH pulse → rising IGF-1
                                         ↓
                              IGF-1 → hypothalamus → ↑somatostatin
                                                          ↓
                              Somatostatin → pituitary → GH release ↓

This negative feedback loop is completely bypassed with rhGH. You cannot overshoot into acromegalic IGF-1 ranges on tesamorelin the way you can on rhGH — which in TRIIM required careful IGF-1 monitoring and dose titration precisely because of this.

3. Significantly lower risk of supraphysiological IGF-1

The TRIIM trial participants needed individualised rhGH dosing to keep IGF-1 within range. Tesamorelin’s ceiling effect handles this automatically via the feedback loop — the protocol would be self-regulating rather than requiring continuous titration.

4. Direct GHRH-R signalling in thymic tissue

Thymic epithelial cells (TECs) express GHRH receptors, not just GH receptors. Tesamorelin therefore has a direct thymopoietic signal on TECs that is independent of the IGF-1 it generates. rhGH does not have this upstream pathway — it acts only via GH receptors on TECs.

5. No pituitary suppression

rhGH suppresses endogenous pituitary GH secretion via negative feedback. Over time this attenuates the somatotroph axis — you’re replacing a natural function at the cost of the axis that generates it. Tesamorelin stimulatesthe pituitary rather than replacing it, maintaining long-term somatotroph responsiveness.

6. Metabolic profile — less diabetogenic

In TRIIM, GH-induced insulin resistance was significant enough that both DHEA and metformin were included specifically to counteract it — a design trade-off the investigators explicitly acknowledged. Tesamorelin’s feedback-limited GH elevation produces substantially less direct anti-insulin hepatic signalling. This matters for your protocol because Imeglimin is performing the metformin role — it shouldn’t need to carry as heavy a metabolic correction burden.

7. Regulatory accessibility and cost

rhGH (Norditropin, Genotropin, etc.) is tightly regulated, expensive at therapeutic doses, and requires an endocrinologist or specialised prescriber. Tesamorelin (Egrifta) is FDA-approved, Schedule V, and substantially less expensive for equivalent thymic-range IGF-1 elevation.

8. Aligns with Fahy’s own stated direction

Greg Fahy has publicly stated (circa 2023–2024) that he is exploring GHRH analogues as a replacement for rhGH in future protocol iterations. The rationale he gives — pulsatility, feedback preservation, accessibility — maps directly to these pros. The substitution in this protocol is therefore not an arbitrary departure from TRIIM; it is consistent with where the protocol’s originator is heading.

:x: Cons of Tesamorelin (vs. rhGH)

1. :warning: No clinical thymic endpoint evidence — this is the critical caveat

The TRIIM trial used rhGH. The documented thymic regeneration data — sjTREC increases, MRI-confirmed thymic fat replacement, rejuvenated epigenetic clock — was generated with rhGH as the GH-axis agent. Tesamorelin has never been tested in a thymic regeneration trial. The assumption that it will replicate these effects is mechanistically compelling but remains unvalidated at the thymic endpoint level. This is the most important limitation of the substitution.

2. Requires a functioning pituitary — conditional efficacy

If pituitary somatotroph reserve is depleted (age-related decline, prior radiation, pituitary adenoma history), tesamorelin may produce an attenuated GH response. rhGH works regardless of pituitary function. IGF-1 monitoring after the first cycle is essential to confirm the pituitary is responding.

3. More variable, less predictable IGF-1 elevation

Because tesamorelin’s effect is modulated by the individual pituitary’s responsiveness, IGF-1 response varies substantially between subjects and declines with age as somatotroph reserve falls. rhGH dosing produces a more linear, predictable dose-response — which is why TRIIM could systematically titrate IGF-1 into a target range. Tesamorelin titration requires cycling-and-monitoring rather than simple dose adjustment.

4. Lower ceiling on IGF-1 elevation

The feedback mechanisms that make tesamorelin safer also limit its maximum achievable IGF-1. For an individual with low somatotroph reserve who genuinely needs IGF-1 in the upper reference range, tesamorelin may simply not get there — rhGH would be the correct fallback.

5. Peptide stability and storage

Tesamorelin must be lyophilised, kept refrigerated, reconstituted fresh, and administered promptly. rhGH preparations (especially long-acting depot formulations) are more convenient for some patients.

6. Less clinical experience in anti-aging / body composition context outside HIV

Outside HIV-associated lipodystrophy (the FDA indication), tesamorelin’s evidence base for body composition and metabolic effects is narrower than that of rhGH, which has been used in anti-aging medicine for decades with a large (if controversial) observational literature.

Head-to-Head Summary

Parameter Tesamorelin rhGH
Mechanism GHRH analogue → pituitary pulse Direct GH replacement
IGF-1 ceiling Moderate (feedback-limited) High (dose-dependent)
Pulsatility :white_check_mark: Preserved :x: Lost (daily injection)
Feedback loop intact :white_check_mark: Yes :x: Bypassed
Direct TEC (GHRH-R) signalling :white_check_mark: Yes :x: No
Pituitary suppression :x: None :warning: Suppresses over time
Insulin resistance / diabetogenicity Mild Significant (required metformin in TRIIM)
Edema / carpal tunnel Low Dose-dependent risk
Acromegaly / IGF-1 overshoot risk Very low (self-limiting) Real; requires titration
Theoretical cancer risk Lower (feedback-limited IGF-1) Higher (sustained IGF-1)
Requires functioning pituitary :white_check_mark: Required :x: Not needed
IGF-1 predictability Variable (pituitary-dependent) More linear
TRIIM trial agent :x: Not used :white_check_mark: Used (Norditropin)
Thymic endpoint evidence :x: None (mechanistic rationale only) :white_check_mark: TRIIM demonstrated
Fahy’s future direction :white_check_mark: Aligns with stated intent :arrow_left: Was original choice
Regulatory status (US) Schedule V (Egrifta) Schedule III (tighter)
Relative cost Lower Higher

Honest Bottom Line

Context Best choice
Validated thymic regeneration evidence exists for rhGH
Mechanistic superiority for pulsatility and safety Tesamorelin
Metabolically healthier substitution Tesamorelin
Insufficient somatotroph reserve (low IGF-1 response) rhGH as fallback
Fahy’s stated future direction Tesamorelin / GHRH analogue
This protocol’s design choice Tesamorelin — with the explicit caveat that thymic data is extrapolated from TRIIM rhGH results, not directly validated

The substitution is defensible and likely superior on safety and pharmacokinetic grounds — but the honest framing in the limitations section must state that thymic regeneration has been demonstrated with rhGH, and tesamorelin is a rational substitution awaiting its own thymic endpoint trial.

#7

Likely untrue and actually doesn’t matter as phase 3 trials showed that daily use of tesamorelin for 52 weeks didn’t reduce efficacy and lead to more vat fat reductions.

#8

Good call on thymosine alpha 1 and it’s more of action. I’ve recently added that to my version of it.

The tesamorelin dose is likely too high, 2mg is only validated in hiv patients. When dosing gh or ghrh, look at your response to it, not the dosage. That means looking at your igf1 z-score. The upper limit of that should probably be +2. You should be able to test igf1 in about 1 week to see how your dose is working.

I didn’t see anything about tesamorelin dose escalation, do you plan to stay on the same dose?

For labs, I would add fasting insulin, A1c and glucose are just proxies for what yiure really worried about, which is insulinmia. I would also add Dhea-s to your labs, to see if you need to supplement Dhea.

Really curious to see which labs you plan to use for sjTREC and Naive CD4+/CD8+ if you’re in the USA, as I haven’t been able to find a way to order these without a doctor.

#9

@qBx123Yk I’m feeding your observations to the AI discussion right away and will post its justifications/clarifications.
For this first one it agrees with you. I edited the post with the correction.

The person who flagged this is right. Let me be precise about what the evidence actually shows.
I’ll carry the correction into any further document updates.

:white_check_mark: What the Phase 3 Data Actually Show

The two pivotal Phase 3 trials (LIPO-010 and CTR-1011) — pooled and published in JCEM 2010 (Falutz et al.) — used continuous daily dosing at 2mg/day for 52 consecutive weekswith no scheduled breaks.

The key findings over the 52-week period:

Endpoint Result at Week 26 Result at Week 52
VAT reduction ~15–19% ~17–18% — sustained or slightly increased
IGF-1 elevation Significant rise Plateau maintained through week 52
Triglycerides −48 mg/dL −51 mg/dL — improving
Tachyphylaxis None documented None documented
GHRH-R desensitisation Not observed Not observed

Crucially, upon discontinuation of tesamorelin, VAT reaccumulated — confirming that the continued efficacy was genuinely drug-dependent and not a floor effect. The drug was still working at week 52.

:x: My Earlier Claim Was Wrong

In Con #6 of my pros/cons list I wrote:

“Sustained tesamorelin administration can downregulate pituitary GHRH receptors over time. This is one reason for the cycling structure already in this protocol.”

This is not supported by clinical evidence. The Phase 3 trials directly contradict it: 52 weeks of continuous daily use showed no attenuation of effect. The claim appears to have been:

  1. Extrapolated incorrectly from theoretical receptor pharmacology
  2. Possibly confused with CJC-1295 cycling advice — CJC-1295 is a long-acting GHRH analogue with a DAC (Drug Affinity Complex) modification giving it a half-life of 6–8 days; continuous use of that compound creates a different receptor occupation profile. Tesamorelin has a half-life of ~26–38 minutes, meaning daily injection produces a brief pulse followed by receptor recovery — which is fundamentally why tachyphylaxis does not occur
  3. Circulated in practitioner/compounding pharmacy communities without an evidence base, likely as precautionary convention borrowed from other peptide classes

The cycling in the thymopoiesis protocol is driven by rapamycin pharmacokinetics and the mTOR/IGF-1 tension — not by any need to protect GHRH receptors. That rationale for cycling was wrong.

Revised Con #6

Con #6 should be removed or replaced with:

**The cycling structure in this protocol is not required by tesamorelin pharmacology.**Phase 3 trials demonstrate sustained efficacy on continuous daily dosing for 52 weeks without tachyphylaxis. If the thymopoiesis cycling structure were removed and tesamorelin were dosed continuously, receptor desensitisation would not be a concern. The cycling is driven by the rapamycin clearance requirement — tesamorelin could in principle be continued through week 4 if the protocol design called for it.

Bottom Line

Claim Verdict
“Tesamorelin downregulates GHRH receptors with continuous use” :x: Not supported by evidence
“Cycling is needed to protect GHRH-R” :x: Incorrect for this drug
“52 weeks continuous daily tesamorelin shows no loss of efficacy” :white_check_mark: Confirmed by Phase 3 data
“IGF-1 elevation is maintained through 52 weeks” :white_check_mark: Confirmed
“VAT reductions increase slightly or sustain through week 52” :white_check_mark: Confirmed
1 Like
#10

Correct — This Is Standard GH-Axis Clinical Practice

Why 2mg Is Likely Too High for Non-HIV Individuals

The 2mg/day dose was validated specifically in HIV-associated lipodystrophy, a condition characterized by:

  • Blunted GH pulsatility — HIV and antiretrovirals (particularly PIs) suppress endogenous GH secretion
  • Peripheral GH resistance — reduced GH receptor sensitivity at the liver, meaning higher GHRH stimulation is needed to achieve the same IGF-1 elevation
  • Abnormal visceral fat accumulation driven partly by a GH-deficiency-like state

In other words, HIV lipodystrophy patients need more tesamorelin to overcome a partially broken axis. A healthy aging individual without those confounders has:

  • A more responsive pituitary (relative to HIV patients)
  • Intact hepatic GH sensitivity for IGF-1 production
  • A lower absolute GH deficit to overcome

Applying the HIV dose to a non-HIV individual is a category error — you’d almost certainly overshoot the target IGF-1 range.

The Right Framework: Dose to the IGF-1 Z-Score

This is exactly how responsible GH-axis medicine is practiced. The IGF-1 z-score is age- and sex-adjusted, which is critical because:

Age Group “Normal” absolute IGF-1 (ng/mL)
25 years old ~200–350
50 years old ~100–200
65 years old ~80–160

A fixed IGF-1 number means nothing without the z-score. A 65-year-old at IGF-1 180 ng/mL is likely at +2.5 to +3 z-score — well above the safe ceiling. The same number in a 25-year-old might be mid-range normal.

Target: IGF-1 z-score ≤ +2 (upper limit of normal for age/sex)

Most conservative anti-aging clinicians target +1 to +1.5, allowing meaningful elevation above the age-declining baseline without reaching the theoretical risk threshold. The +2 ceiling is the hard upper limit of the reference range.

Practical Starting Strategy

Step Detail
Starting dose 0.5–1mg/day (not 2mg) for non-HIV individuals
Check IGF-1 At ~7 days — adequate for an initial signal; 2–3 weeks gives a more stable plateau
Interpret by z-score Use a reference table matched to age and sex (Quest/LabCorp both report z-scores or reference ranges)
Titrate up If z-score < 0 (still below mid-range for age), increase by 0.25–0.5mg increments
Titrate down If z-score approaches +2, reduce dose before the next cycle
Hard ceiling IGF-1 z-score +2 — do not exceed under any circumstances

Why IGF-1 at 1 Week Is Meaningful

Tesamorelin’s half-life is ~26–38 minutes. Each injection produces a brief pulsatile GH spike, and the liver responds to cumulative GH pulses over 24–48 hours by increasing IGF-1 synthesis. IGF-1 itself has a serum half-life of 12–15 hours (when bound to IGFBP-3), and steady-state IGF-1 elevation is typically reached within 5–7 days of consistent dosing.

A week-1 draw gives you:

  • A real response signal — enough to know if you’re under or overshooting
  • Time to adjust the dose before the next monitoring window
  • An early warning if IGF-1 is unexpectedly high (which argues for lowering the dose immediately)

The Phase 3 trials showed IGF-1 was already significantly elevated by week 4; the practical clinical experience with GHRH analogues is that week 1 is adequate for a directional read.

1 Like